Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study.
The effect of high dose intravenous immunoglobulin (IVIg) treatment was studied in six patients with multifocal motor neuropathy (MMN). All patients responded to treatment (0.4 g/kg for five consecutive days) in an open trial. The effect of IVIg treatment was confirmed for each patient in a single patient, double blind, placebo controlled trial. Four patients received two IVIg treatments and two placebo treatments, and two patients received one IVIg and one placebo treatment in a randomised order. Five out of six patients responded to IVIg but not to placebo. One patient responded to IVIg in the same manner as to placebo treatment. Thus IVIg treatment can lead to improvement of muscle strength in patients with MMN.
Van den Berg
L H
LH
Rudolf Magnus Research School in the Neurosciences, Department of Neurology, University Hospital Utrecht, The Netherlands.
Kerkhoff
H
H
Oey
P L
PL
Franssen
H
H
Mollee
I
I
Vermeulen
M
M
Jennekens
F G
FG
Wokke
J H
JH
D000328:Adult; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D016472:Motor Neuron Disease / Q000503:physiopathology / Q000628:therapy*; D009132:Muscles / Q000503:physiopathology
D016756:Immunoglobulins, Intravenous